Evidence map›Paper›PMID 36015223›Full record

ArticlePharmaceutics2022

A Pseudovirus Nanoparticle-Based Trivalent Rotavirus Vaccine Candidate Elicits High and Cross P Type Immune Response.

Ming Xia, Pengwei Huang, Ming Tan

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The αTSR Domain ofInternational journal of nanomedicine · 2023
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ming XiaDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.ORCID 0000-0002-0408-5828
Pengwei HuangDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.ORCID 0000-0002-8439-3088
Ming TanDivision of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.ORCID 0000-0002-6489-5507
Cincinnati Children's Hospital Medical Center · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
A Nanoparticle-Based Multivalent Rotavirus VaccineR56AI148426 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI TAN, MING · 2020 to 2020
$626k
Cincinnati Children's Hospital Medical Center GAP Fund 2020Cincinnati Children's Hospital Medical Center Innovation Fund 2019Cincinnati Children's Hospital Medical Center Innovation Fund 2020National Institute of Allergy and Infectious Diseases 1 R56 AI148426-01A1NCATS NIH HHS UL1 TR001425NIAID NIH HHS R56 AI148426The National Center for Advancing Translational Sciences of the National Institutes of Health UL1TR001425
6 · The paper itself

Abstract

Rotavirus infection continues to cause significant morbidity and mortality globally. In this study, we further developed the S

Indexed as

non-replicating rotavirus vaccinenorovirus S60 nanoparticlerotavirusrotavirus vaccinerotavirus VP8*S60-VP8* pseudovirus nanoparticle

Identifiers

PMID36015223
PMCPMC9413348
OpenAlexW4289204701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.